Safety and early evidence of activity of a first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with selected solid tumors A.

First Page		Document Content
Date: 2014-11-19 14:29:45		Safety and early evidence of activity of a first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with selected solid tumors A. Add to Reading List Source URL: s3.amazonaws.com Download Document from Source Website File Size: 1,17 MB Share Document on Facebook